Medivir AB (Nasdaq Stockholm: MVIR) today announces a new discovery
project for a cancer indication, a liver targeted nucleotide prodrug for
the treatment of hepatocellular carcinoma (HCC). The project is based on
the company’s expertise in nucleoside and nucleotide science and is the
first cancer project to emerge from its in-house discovery efforts in
oncology that were announced in 2014.
“Our HCC nucleotide project has made very rapid progress after its
initiation last year” said Richard Bethell, EVP Discovery Research. “We
have identified molecules with excellent activity against a range of HCC
cell lines and with the required distribution properties to enable them
to be delivered selectively to the liver. Preclinical testing of these
molecules in relevant models of HCC will begin early in the third
quarter.”
Hepatocellular carcinoma is the most common cancer of the liver. Liver
cancer is the second leading cause of cancer-related death world-wide,
and one of the fastest growing cancers in the US based on incidence and
mortality.
Medivir is required under the Securities Markets Act to make the
information in this press release public. The information was submitted
for publication at 08.30 CET on 30 June 2015.
About Medivir
Medivir is a research based pharmaceutical company with a research focus
on infectious diseases and oncology. We have a leading competence within
protease inhibitor design and nucleotide/nucleoside science and we are
dedicated to develop innovative pharmaceuticals that meet great unmet
medical need. Our commercial organization provides a growing portfolio
of specialty care pharmaceuticals on the Nordic market. Medivir is
listed on the Nasdaq Stockholm Mid Cap List.
This information was brought to you by Cision http://news.cision.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20150629006424/en/
Copyright Business Wire 2015